CD79B: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of CD79B. The page also collects GeneMedi's different modalities and formats products for CD79B in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the CD79B target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
The B lymphocyte antigen receptor is a multimeric complex that includes the antigen-specific component, surface immunoglobulin (Ig). Surface Ig non-covalently associates with two other proteins, Ig-alpha and Ig-beta, which are necessary for expression and function of the B-cell antigen receptor. This gene encodes the Ig-beta protein of the B-cell antigen component. Alternatively spliced transcript variants encoding different isoforms have been described. [provided by RefSeq, Jul 2008]
| Target ID | GM-T08306 |
| Target Name | CD79B |
| Gene ID | 974,15985,171055,718218,609449,101098098,509801,100064460 |
| Gene Symbol and Synonyms | AGM6,B29,CD79B,Ig-beta,IGB,Igbeta |
| Uniprot Accession | P40259 |
| Uniprot Entry Name | CD79B_HUMAN |
| Protein Sub-location | Transmembrane Protein |
| Category | Therapeutics Target, INN Index |
| Disease | Cancer |
| Gene Ensembl | ENSG00000007312 |
| Target Classification | Tumor-associated antigen (TAA) |
Pre-made CD79B-specific INN-index biosimilar (antibody&conjugates)
Anti-CD79B therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
| Cat No. | Products Name (INN Index) | INN Name | Previous Name | Target | Format | Detail |
| GMP-Bios-INN-962 | Pre-Made Polatuzumab Vedotin Biosimilar, Whole Mab Adc, Anti-Cd79B Antibody: Anti-AGM6/B29/IGB therapeutic antibody Drug Conjugate | polatuzumab vedotin | CD79B | Whole mAb ADC | Detail | |
| GMP-Bios-INN-862 | Pre-Made Iladatuzumab Vedotin Biosimilar, Whole Mab Adc, Anti-Cd79B Antibody: Anti-AGM6/B29/IGB therapeutic antibody Drug Conjugate | iladatuzumab vedotin | CD79B | Whole mAb ADC | Detail | |
| GMP-Bios-ab-264 | Pre-Made Iladatuzumab biosimilar, Whole mAb ADC, Anti-CD79B Antibody: Anti-AGM6/B29/IGB therapeutic antibody | Iladatuzumab | CD79B | Whole mAb ADC | Detail | |
| GMP-Bios-ab-449 | Pre-Made Polatuzumab biosimilar, Whole mAb ADC, Anti-CD79B Antibody: Anti-AGM6/B29/IGB therapeutic antibody | Polatuzumab | CD79B | Whole mAb ADC | Detail |
Click to check more INN-indexed antibody & protein biosimilar
Pre-made anti-CD79B inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-CD79B benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-CD79B mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Antibody Name | Species | Format | Classified by tag | Detail |
| Anti-CD79B monoclonal antibody | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | mab | FACS/Biofunctional Antibody, Therapeutics Target antibody | Detail |
Multi-species CD79B/ AGM6/ B29 VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine CD79B VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
| Products Name | Species | Expression Platform | Detail |
| CD79B VLP (virus-like particle) | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | Mammalian cell | Products Developing |
Pre-made CD79B viral vector in GM Promise-ORFTM
| Cat No. | Products name | NM ID | Species | Type | Detail |
| vGMLP000751 | human CD79B Lentivirus particle | NM_000626.3 | Human | Lentivirus particle | Detail |
| pGMLP000751 | human CD79B Lentivirus plasmid | NM_000626.3 | Human | Lentivirus plasmid | Detail |
About Promise-ORFTM:
Discover the largest collection of ORF/cDNA expression clones from different species, including human, mouse, rat, and more with GeneMedi's Promise-ORFTM. Our collection of ORFs expression clones come in verified mammalian or viral vectors lentivirus, AAV, and adenovirus) and our Promise-ORFTM viral-ready expression vectors make it easy for you to improve viral vector packaging efficiency or directly transfect mammalian cells, resulting in stronger and easier expression detection. Click to search your GOI
If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service.
Facebook
LinkedIn
Twitter
